Latest news with #PiramalPharma
Business Standard
3 days ago
- Business
- Business Standard
Piramal Pharma's Canada facility gets zero USFDA observation
Piramal Pharma announced that the United States Food and Drug Administration (USFDA) has completed a general good manufacturing practices (GMP) inspection at its manufacturing facility in Aurora, Canada. According to a regulatory filing, the inspection was carried out from 26 May 2025 to 30 May 2025. At the conclusion of the inspection, the USFDA issued a zero-observation report in Form 483 and granted a no action indicated (NAI) designation. The company remains dedicated to maintaining the highest standards of compliance. Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products. The companys consolidated net profit jumped 51.6% to Rs 153.50 crore on 7.9% rise in revenue from operations to Rs 2,754.07 crore in Q4 FY25 over Q4 FY24. Shares of Piramal Pharma rose 0.36% to Rs 207.05 on the BSE.
Business Upturn
4 days ago
- Business
- Business Upturn
Piramal Pharma successfully clears US FDA GMP inspection at Aurora facility
By Aman Shukla Published on June 2, 2025, 10:32 IST Piramal Pharma Limited has successfully completed the US FDA Good Manufacturing Practices (GMP) inspection at its Aurora, Canada facility. The inspection took place from May 26 to May 30, 2025. The US FDA conducted a thorough general GMP inspection, evaluating the facility's compliance with stringent manufacturing standards. Piramal Pharma's Aurora site was awarded a clean slate with zero Form 483 observations and received a No Action Indicated (NAI) designation, underscoring its commitment to excellence and regulatory compliance. This successful inspection reinforces Piramal Pharma's position as a leading pharmaceutical company dedicated to maintaining the highest quality standards in drug manufacturing. The company continuously strives to ensure the safety, efficacy, and quality of its products for patients worldwide. This successful inspection reinforces Piramal Pharma's position as a leading pharmaceutical company dedicated to maintaining the highest quality standards in drug manufacturing. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Economic Times
22-05-2025
- Business
- Economic Times
Exploring the Growth Potential of the Indian Pharmaceutical Sector
Sector Performance and Outlook Top Companies Analysts Recommend Based on Upside Potential Company Name Current Price Target Price Upside Potential Recommendation Cohance Lifesciences Limited Rs. 1065.4 Rs. 1400.00 33% Strong Buy Piramal Pharma Rs. 205.74 Rs. 271.00 32% Strong Buy Natco Pharma Rs. 870.1 Rs. 1090.00 28% Hold Aurobindo Pharma Rs. 1182 Rs. 1470.00 23% Buy Blue Jet Healthcare Rs. 794.3 Rs. 943.00 19% Buy Zydus Lifesciences Rs. 906.65 Rs. 1040.00 18% Hold Cohance Lifesciences Live Events Piramal Pharma Natco Pharma Aurobindo Pharma Blue Jet Healthcare Zydus Lifesciences (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel The Indian pharmaceutical sector has demonstrated a robust growth trajectory, with a notable increase in performance over the past year. The sector has benefitted from a new trade agreement with the European Union, which aims to reduce tariffs on key drug exports. This agreement is expected to enhance India's position as a global supplier of generic medicines , leading to increased trade volume and job creation within the the short term, the sector has shown positive momentum, reflecting a steady rise in investor confidence. The long-term implications of the trade agreement include improved access to European markets and potential technology transfer, which could significantly bolster India's pharmaceutical innovation capabilities. Overall, the outlook for the sector remains positive, with analysts projecting substantial upside potential for various companies operating within this space. Cohance Lifesciences Limited , formerly known as Suven Pharmaceuticals Limited, is a technology-driven contract development and manufacturing organization(CDMO)based in India. The company specializes in providing integrated solutions in custom synthesis, process research and development, and manufacturing. Its business units include pharmaceutical CDMO, specialty chemical CDMO, and active pharmaceutical ingredient(API) have a strong buy recommendation for Cohance Lifesciences, with a target price of Rs. 1400.00, indicating an upside potential of 33%. The company has shown impressive financial performance, with a year-on-year PAT growth of 77.27%, despite a slight decline in sales growth of 21.56%. Piramal Pharma Limited is a global pharmaceutical company offering a diverse portfolio of differentiated pharma products across a domestic and global distribution network. The company operates approximately 17 development and manufacturing facilities across India, the UK/Europe, and North a strong buy recommendation from analysts, Piramal Pharma has a target price of Rs. 271.00, reflecting an upside potential of 32%. The latest financial data shows a sales growth of 11.99% year-on-year, although the PAT stands at Rs. 153.5 Cr. Natco Pharma Limited is an India-based vertically integrated pharmaceutical company focused on research and development. The company specializes in developing, manufacturing, and commercializing complex pharmaceuticals targeting specific therapeutic recommend holding Natco Pharma, with a target price of Rs. 1090.00, indicating an upside potential of 28%. The latest financial results reveal a significant year-on-year sales growth of 47.72%, although PAT has decreased by 37.47% compared to the previous year. Aurobindo Pharma Limited is engaged in the manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, and generic pharmaceuticals. The company has a global presence, marketing its products in approximately 150 a buy recommendation from analysts, Aurobindo Pharma has a target price of Rs. 1470.00, reflecting an upside potential of 23%. The company reported a year-on-year sales growth of 16.68%, although PAT has decreased by 9.66% in the latest quarter. Blue Jet Healthcare Limited specializes in manufacturing integrated contrast media, artificial sweeteners, and niche pharmaceutical intermediaries. The company operates primarily as a business-to-business entity, serving various industries have a buy recommendation for Blue Jet Healthcare, with a target price of Rs. 943.00, indicating an upside potential of 19%. The company has demonstrated remarkable financial growth, with a year-on-year PAT growth of 177.64% and sales growth of 44.74%. Zydus Lifesciences Limited is a global life sciences company engaged in discovering, developing, manufacturing, and marketing a broad range of healthcare therapies. The company has a diverse product portfolio, including active pharmaceutical ingredients and human recommend holding Zydus Lifesciences, with a target price of Rs. 1040.00, reflecting an upside potential of 18%. The company has reported a year-on-year sales growth of 18.9%, although PAT has decreased by 5.79% in the latest quarter.
Time of India
22-05-2025
- Business
- Time of India
Exploring the Growth Potential of the Indian Pharmaceutical Sector
Sector Performance and Outlook The Indian pharmaceutical sector has demonstrated a robust growth trajectory, with a notable increase in performance over the past year. The sector has benefitted from a new trade agreement with the European Union, which aims to reduce tariffs on key drug exports. This agreement is expected to enhance India's position as a global supplier of generic medicines , leading to increased trade volume and job creation within the sector. In the short term, the sector has shown positive momentum, reflecting a steady rise in investor confidence. The long-term implications of the trade agreement include improved access to European markets and potential technology transfer, which could significantly bolster India's pharmaceutical innovation capabilities. Overall, the outlook for the sector remains positive, with analysts projecting substantial upside potential for various companies operating within this space. Top Companies Analysts Recommend Based on Upside Potential Company Name Current Price Target Price Upside Potential Recommendation Cohance Lifesciences Limited Rs. 1065.4 Rs. 1400.00 33% Strong Buy Piramal Pharma Rs. 205.74 Rs. 271.00 32% Strong Buy Natco Pharma Rs. 870.1 Rs. 1090.00 28% Hold Aurobindo Pharma Rs. 1182 Rs. 1470.00 23% Buy Blue Jet Healthcare Rs. 794.3 Rs. 943.00 19% Buy Zydus Lifesciences Rs. 906.65 Rs. 1040.00 18% Hold Cohance Lifesciences Cohance Lifesciences Limited , formerly known as Suven Pharmaceuticals Limited, is a technology-driven contract development and manufacturing organization(CDMO)based in India. The company specializes in providing integrated solutions in custom synthesis, process research and development, and manufacturing. Its business units include pharmaceutical CDMO, specialty chemical CDMO, and active pharmaceutical ingredient(API)services. Analysts have a strong buy recommendation for Cohance Lifesciences, with a target price of Rs. 1400.00, indicating an upside potential of 33%. The company has shown impressive financial performance, with a year-on-year PAT growth of 77.27%, despite a slight decline in sales growth of 21.56%. Piramal Pharma Piramal Pharma Limited is a global pharmaceutical company offering a diverse portfolio of differentiated pharma products across a domestic and global distribution network. The company operates approximately 17 development and manufacturing facilities across India, the UK/Europe, and North America. With a strong buy recommendation from analysts, Piramal Pharma has a target price of Rs. 271.00, reflecting an upside potential of 32%. The latest financial data shows a sales growth of 11.99% year-on-year, although the PAT stands at Rs. 153.5 Cr. Natco Pharma Natco Pharma Limited is an India-based vertically integrated pharmaceutical company focused on research and development. The company specializes in developing, manufacturing, and commercializing complex pharmaceuticals targeting specific therapeutic areas. Analysts recommend holding Natco Pharma, with a target price of Rs. 1090.00, indicating an upside potential of 28%. The latest financial results reveal a significant year-on-year sales growth of 47.72%, although PAT has decreased by 37.47% compared to the previous year. Aurobindo Pharma Aurobindo Pharma Limited is engaged in the manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, and generic pharmaceuticals. The company has a global presence, marketing its products in approximately 150 countries. With a buy recommendation from analysts, Aurobindo Pharma has a target price of Rs. 1470.00, reflecting an upside potential of 23%. The company reported a year-on-year sales growth of 16.68%, although PAT has decreased by 9.66% in the latest quarter. Blue Jet Healthcare Blue Jet Healthcare Limited specializes in manufacturing integrated contrast media, artificial sweeteners, and niche pharmaceutical intermediaries. The company operates primarily as a business-to-business entity, serving various industries globally. Analysts have a buy recommendation for Blue Jet Healthcare, with a target price of Rs. 943.00, indicating an upside potential of 19%. The company has demonstrated remarkable financial growth, with a year-on-year PAT growth of 177.64% and sales growth of 44.74%. Zydus Lifesciences Zydus Lifesciences Limited is a global life sciences company engaged in discovering, developing, manufacturing, and marketing a broad range of healthcare therapies. The company has a diverse product portfolio, including active pharmaceutical ingredients and human formulations. Analysts recommend holding Zydus Lifesciences, with a target price of Rs. 1040.00, reflecting an upside potential of 18%. The company has reported a year-on-year sales growth of 18.9%, although PAT has decreased by 5.79% in the latest quarter.
Mint
19-05-2025
- Business
- Mint
The market is punishing Piramal Pharma. Is it an overreaction?
Piramal Pharma Ltd has more than tripled investor wealth since 2023-24. With the Mumbai-based drug development and manufacturing company turning around its business recently, its stock has significantly outperformed the Nifty Pharma index the past two years. So why has the stock eroded 30% of investor wealth since its peak in November? Already weighed down by global policy uncertainty, the Piramal Pharma counter has extended its correction after its earnings for the fourth quarter of 2024-25 disappointed investors. But is the correction an opportunity for investors to buy the stock, or a signal of more stress to come? From turnaround to disappointment Piramal Pharma is one of India's leading pharmaceutical companies with 17 manufacturing and development sites, and commercial presence in more than 100 countries. Its spick-and-span quality track-record speaks for itself—the company has successfully cleared almost 50 inspections of its global facilities by the US Food and Drug Administrator since FY12. Piramal Pharma's financials had been under stress but the company turned around its business. From FY23 to FY25, its revenue grew at a compound annual growth rate of 14%, and its EBITDA margin expanded from 12% to 17%. And from a loss of ₹186 crore in FY23, Piramal Pharma swung to a profit of ₹91 crore in FY25. Importantly, the turnaround was accompanied by a moderation in debt—net debt to EBITDA dropped from 5.6x to 2.7x during the period. But Piramal Pharma's latest fourth-quarter results disappointed investors. Revenue growth was muted at 8% year-on-year and EBITDA margin was flat at 22%. While profit increased 52%, a bulk of the growth was due to a rights write-off undertaken in the base quarter. Also read | Defence stocks are soaring again, but can fundamentals support the rally? Mainstay segment led growth in FY25 Piramal Pharma operates in three key segments. Its contract development and manufacturing organization (CDMO) business contributed 59% of its revenue in FY25 and its complex hospital generics (CHG) business, which includes products such as anesthesia and intrathecal therapy, accounted for 29%. The balance 12% contribution came from its India consumer healthcare (ICH) business, which deals in over-the-counter consumer and wellness products. Piramal Pharma's mainstay segment, CDMO, registered a slightly higher share of innovation-related work last year—54% in FY25 vs 50% in FY24. It also scored a 54% surge in on-patent commercial manufacturing. The result: The company's CDMO business delivered 15% year-on-year growth in FY25, supporting overall revenue growth of 12%. EBITDA margin for the segment also improved, thanks to improved efficiencies in procurement and operations. The tariff uncertainty effect Pharmaceuticals are currently not under the purview of the US's reciprocal tariffs on products exported to the country. But US President Donald Trump has indicated that discussions are underway to strip the pharma sector of this exemption. If that happens, it would significantly hurt India's pharma sector, which counts the US as its biggest market for pharmaceutical products manufactured in India, including generic or off-patent drugs and pricier branded products. Indian pharma companies will face steeply higher production costs if they have to move their manufacturing to the US as a result of Trump's reciprocal tariffs, which have been suspended until 9 July. Piramal Pharma, which derives more than a third of its revenue from North America, has already invested $470 million in its manufacturing facilities in the US. Additional capital expenditure of $90 million is in the works. Also read | Why Tata Teleservices is drawing institutional bets despite mounting losses Making matters worse: Trump's drug-pricing order Despite higher manufacturing costs in the US, higher prices of on-patent drugs in the market could have made manufacturing such products there financially feasible. But the latest twist in the tale is Trump's executive order asking pharma companies to slash the prices of on-patent drugs in the US to match the cheapest global prices. Also read | Mint Explainer: Why Indian pharma is spooked by Trump's latest drug policy Given that Piramal's CDMO customer-mix is skewed towards big pharma and emerging biopharma, with only 39% exposure to generics, the company is at risk if Trump's drug price order goes through. The uncertainty has frayed investors' nerves. Biotech funding in the US has seen uneven improvement, leading to selective and delayed order placement. The customer concentration risk at Piramal's CDMO business has exacerbated the circumstances. While it has over 500 customers, its top 10 customers contribute almost half of the business. Consequently, Piramal's overseas CDMO sites are operating significantly below capacity. This has reduced operating leverage even as operating expenses rise on account of a new manufacturing facility. Revenue growth in CDMO for Piramal is expected to be in single digits in FY26, with EBITDA margin likely to remain stressed. Also read | Chalet Hotels is gearing up for a major expansion. Should investors check in now? India business offers comfort Piramal Pharma's CDMO sites in India contribute 6% to its business, and have been operating at healthy utilizations. The company's India consumer healthcare (ICH) business has also matched pace with overall growth, registering an 11% increase in revenue. Driven by 52 new products and stock-keeping units (or product lines) launched in FY25, the ICH business crossed the ₹1,000 crore milestone during the year. About 49% of Piramal's ICH business came from power brands such as Lacto Calamine, Little's, and CIR, helping it post a robust 20% rise in fourth-quarter revenue. About 21% of the segment's sales came from e-commerce, which registered an overall 39% year-on-year growth for Piramal Pharma in FY25. This negated a slowdown in Piramal Pharma's i-range products (i-Pill emergency contraceptive, i-Know home kits for pregnancy and other tests, etc.) brought about by regulatory price controls. Prospects for inorganic growth remain open as well. While Piramal Pharma has clarified that it won't be re-entering the domestic prescription formulations business, it may consider acquiring domestic over-the-counter portfolios. Complex hospital generics: Cautious optimism Piramal's CHG segment posted an 8% year-on-year revenue growth in FY25, the slowest among all its segments. It also dragged down Piramal's overall margin due to one-time expenses and capacity expansion in India. But the facility is now operational and expected to deliver revenues starting FY26. Piramal Pharma has also managed to hang on to its leading market share in its primary businesses—inhaled anesthetics and intrathecal therapy. It commands a 75% share of the US market in intrathecal baclofen, and a 44% share in inhaled anesthetics through the industry-leading 'Sevoflurane'. Sevoflurane accounts for 86% of the $1 billion global inhaled anesthetics market. Piramal Pharma plans to leverage its Sevoflurane facilities to try and capture the $400 million market for the drug outside the US and China. Recent launches have further improved prospects for Piramal Pharma's CHG business. In 2025, Piramal launched an injectable to treat psychiatric disorders, and has received commercialization rights for the neonatal cardiovascular drug 'Neoatricon'. The management aims to grow the segment to $600 million by FY30. CDMO pipeline propels hopes To cater to rising US consumer demand, Piramal recently announced new capital expenditure worth $90 million in its US CDMO facilities at Lexington and Riverview. This should help it capture a larger share of antibody-drug-conjugates (ADCs) and injectables. The injectables market is projected at $20 billion by 2028. The segment also boasts of 2.8x expansion in its development pipeline from 52 products in FY17 to 145 in FY25. Another tailwind can come from the US Biosecure Act, which if approved will benefit Indian CDMOs by prohibiting imports of biotechnology equipment from China. Piramal's management aims to grow its CDMO business to $1.2 billion by FY30. Short-term volatility Notwithstanding the near-term headwinds, Piramal has affirmed its FY30 outlook of $2 billion in revenue with 25% EBITDA margin and 1x net debt/EBITDA. Brokerages expect the company's profit before tax (PBT) margin to expand to 16% by FY28. But short-term volatility cannot be ruled out. Brokerages have slashed their price target for Piramal to a wide range from ₹230 to ₹340 per share. Introduction of futures and options (F&O) contracts on the counter at the end of this month can also add to the volatility. At 2.45 pm on Monday, Piramal Pharma shares were up about 0.30% at ₹205.50 apiece, down from a 2% jump earlier in the day. Nifty Pharma was up about 0.70%. Ananya Roy is the founder of Credibull Capital, a Sebi-registered investment adviser. Disclosure: The author does not hold shares of the companies discussed. The views expressed are for informational purposes only and should not be considered investment advice. Readers are encouraged to conduct their own research and consult a financial professional before making any investment decisions.
